Abstract: The present disclosure relates to a method for labeling a radioisotope, a radiolabeling compound, a kit including the same, and a method for labeling a radioisotope, including: providing a diaminophenyl compound represented by Chemical Formula I below and including a biomolecule, a fluorescent dye or a nanoparticle compound bound thereto; and reacting the diaminophenyl compound and a radioisotope-labeled aldehyde compound represented by Chemical Formula II below at room temperature; and a related technology: in Chemical Formula I, A is CH2 or O; a is 0 or an integer of 1 to 10; X is CH2 or —CONH—; Y is CH2 or ?and Z is the biomolecule, the fluorescent dye or the nanoparticle compound, in Chemical Formula II, b is 0 or an integer of 1 to 10; and L is CH2 or —CONH—; and Q is M, M? and M? in Q are radioisotopes.

Abstract: The present disclosure relates to a method for labeling a radioisotope, a radiolabeling compound, a kit including the same, and a method for labeling a radioisotope, including: providing a diaminophenyl compound represented by Chemical Formula I below and including a biomolecule, a fluorescent dye or a nanoparticle compound bound thereto; and reacting the diaminophenyl compound and a radioisotope-labeled aldehyde compound represented by Chemical Formula II below at room temperature; and a related technology: in Chemical Formula I, A is CH2 or O; a is 0 or an integer of 1 to 10; X is CH2 or —CONH—; Y is CH2 or and Z is the biomolecule, the fluorescent dye or the nanoparticle compound, in Chemical Formula II, b is 0 or an integer of 1 to 10; and L is CH2 or —CONH—; and Q is or M, M? and M? in Q are radioisotopes.

Abstract: A process for removing iodine using gold particles includes contacting a solution including iodine, with gold particles. The iodine is adsorbed onto the gold particles and then removed. A device for removing iodine using gold particles includes gold particles in a stationary phase and is configured to contact a solution including iodine, with gold particles, to thus adsorb the iodine onto the gold particles and remove the iodine.

Abstract: A process for removing iodine using gold particles includes contacting a solution including iodine, with gold particles. The iodine is adsorbed onto the gold particles and then removed. A device for removing iodine using gold particles includes gold particles in a stationary phase and is configured to contact a solution including iodine, with gold particles, to thus adsorb the iodine onto the gold particles and remove the iodine.

Abstract: The present invention relates to a pharmaceutical composition for the prevention and treatment of tissue injury caused by irradiation which comprises silkworm hemolymph as an active ingredient. Particularly, when the silkworm hemolymph of the present invention was administered to an animal model with liver damage induced by irradiation, plasma AST and liver MDA were significantly decreased, indicating that the silkworm hemolymph of the invention can be effectively used as a composition for the prevention and treatment of disease caused by the exposure on radiation including tissue injury caused by irradiation, etc.

Abstract: The present invention relates to a pharmaceutical composition for the prevention and treatment of tissue injury caused by irradiation which comprises silkworm hemolymph as an active ingredient. Particularly, when the silkworm hemolymph of the present invention was administered to an animal model with liver damage induced by irradiation, plasma AST and liver MDA were significantly decreased, indicating that the silkworm hemolymph of the invention can be effectively used as a composition for the prevention and treatment of disease caused by the exposure on radiation including tissue injury caused by irradiation, etc.

Abstract: Disclosed is a technetium-99m-labeled glycine oligomer associated with imaging probes for biomolecules of interest. The glycine oligomer can be readily synthesized in a single process using an automated peptide synthesizer. The technetium-99m tricarbonyl-labeled glycine oligomers can be useful as a radiotracer for gamma or SPECT imaging apparatus. The technetium-99m tricarbonyl-labeled glycine oligomers can be applied to various peptidyl biomolecules such as RGD peptide, somatostatin, neurotensin, etc., and exhibit rapid renal clearance without being excessively retained within the body.

Abstract: There is provided a method for preparing a 99mTc labeled gold nanoparticles-gold binding peptide, including: (a) coating gold nanoparticles with a gold binding peptide; and (b) labeling a composed 99mTc tricarbonyl precursor on the gold binding peptide coated on the gold nanoparticles. The 99mTc labeled gold nanoparticles-gold binding peptide prepared by the method according to the present invention is expected to be usefully employed for manufacturing a molecular contrast agent (imaging agent) which is traceable in organisms using imaging apparatuses such as gamma imaging and single photon emission computed tomography due to high labeling yield and good in-vivo stability.

Abstract: A method for labelling a sulfide compound with technetium or rhenium, comprising the reaction of a disulfide compound with pertechnetate or perrhenate in the presence of borohydride exchange resin to obtain a complex of technetium or rhenium with the sulfide compound. The method can directly label disulfide compounds with technetium or rhenium, can skip the synthetic step of thiol-protected S-precursor, and is useful for high value-added radiopharmaceuticals.

Abstract: The present invention relates to a method of preparing technetium or rhenium complex for radiopharmaceuticals, through reaction of pertechnetate or perrhenate with a ligand in the presence of a reducing agent, wherein the reducing agent is a borohydride exchange resin (BER). The borohydride exchange resin of the present invention has advantages of being stable in a wide range of Ph, including acidic or alkaline condition(Ph 2˜14) and thus being applicable to biological materials as well as being easily removable through filtration when being administrated. Also since the radiolabelled complex is produced under conditions milder than those required for the conventional reducing agents as well as has high radiochemical purity and high labeling efficiency, the conventional reducing agents can be replaced by the BER of the present invention.

Abstract: The present invention relates to a method of preparing technetium or rhenium complex for radiopharmaceuticals, through reaction of pertechnetate or perrhenate with a ligand in the presence of a reducing agent, wherein the reducing agent is a borohydride exchange resin (BER) . The borohydride exchange resin of the present invention has advantages of being stable in a wide range of Ph, including acidic or alkaline condition(Ph 2˜14) and thus being applicable to biological materials as well as being easily removable through filtration when being administrated. Also since the radiolabelled complex is produced under conditions milder than those required for the conventional reducing agents as well as has high radiochemical purity and high labeling efficiency, the conventional reducing agents can be replaced by the BER of the present invention.

Abstract: The present invention relates to a method for labelling a sulfide compound with technetium or rhenium, comprising the reaction of a disulfide compound with pertechnetate or perrhenate in the presence of borohydride exchange resin to obtain a complex of technetium or rhenium with the sulfide compound. The method can directly label disulfide compounds with technetium or rhenium, can skip the synthetic step of thiol-protected S-precursor, and is useful for high value-added radiopharmaceuticals.